At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Rybelsus (semaglutide) is a brand-name prescription medication that ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce certain risks associated with chronic kidney disease.

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy, in May 2022 and lost a staggering 64lbs in six months. But then she made a big ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy. The notice was issued on Tuesday ...

Compounded semaglutide is typically cheaper than branded ... In November, the Biden administration proposed a new rule to expand Medicare and Medicaid coverage to include GLP-1s for weight loss ...

Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...

Marni Rose McFall is a Newsweek reporter based in London, U.K. Her focus is on U.S. politics, social affairs and popular culture. She has covered fashion, culture, art and music extensively. Marni ...

The agency announced last week that Ozempic and Wegovy, along with Novo's other semaglutide GLP-1 diabetes drug Rybelsus, are at the top of its list for 2027 Medicare drug price negotiations.